Medicamento autorizado
Un regulador lo ha autorizado para al menos un uso, en al menos un país. Eso no dice nada sobre usos fuera de la licencia.
Esta página es un esbozo
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
Qué tan sólida es la evidencia
Hasta dónde ha llegado
Todo medicamento sube la misma escalera. La mayoría de los compuestos nunca llega a lo más alto, y el lugar que ocupa indica cuánto pueden sostener sus afirmaciones.
- Medicamento autorizado: Teriparatide
Un regulador ha revisado los ensayos y lo ha autorizado para un uso concreto.
- Fase 3
Ensayos aleatorizados grandes, a menudo con miles de personas, frente a placebo o un tratamiento estándar.
- Fase 2
Ensayos de tamaño medio que miden la dosis frente al efecto en personas con la enfermedad.
- Fase 1 y estudios humanos iniciales
Primeros estudios en personas: seguridad y cómo el organismo lo procesa.
- Células y animales
Trabajo de laboratorio y con animales. Un resultado en animales no es un resultado en personas.
- 1,466
- artículos en PubMed
- 979
- de ellos en personas
- 221
- ensayos aleatorizados
- 172
- revisiones
Un recuento indica cuánto se ha publicado, no lo que encontró. Contado en PubMed: 2026-11-16
Manipulación y reconstitución
Del polvo a una muestra medida
Los mismos cuatro pasos para cualquier vial liofilizado. Manipulación de laboratorio, no uso en una persona.
1. Lea el vial
La etiqueta indica la masa de péptido en el vial, en miligramos. Ese número es el punto de partida de todo cálculo.
2. Añada el diluyente
Se añade un volumen medido de diluyente lentamente, por la pared del vidrio. Haga girar con suavidad; agitar puede dañar un péptido.
3. Calcule la concentración
La concentración es la masa dividida por el volumen: 10 mg en 2 mL son 5 mg por mL.
4. Mida la muestra
El volumen es la masa deseada dividida por la concentración. En una jeringa U-100, 1 mL equivale a 100 unidades.
La calculadora de abajo hace la aritmética y muestra el procedimiento.
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on Teriparatide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Teriparatide; no amount here is a recommendation.
Teriparatide: en PubMed
What PubMed held for Teriparatide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 1,466
- papers
- 979
- in humans
- 280
- clinical trials
- 221
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Randomized trialLeder BZ, Tsai JN, Uihlein AV, et al. Lancet (London, England), 2015. PMID 26144908
- Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials
Meta-analysisLi M, Ge Z, Zhang B, et al. Archives of osteoporosis, 2024. PMID 39312040
- Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Randomized trialTsai JN, Uihlein AV, Lee H, et al. Lancet (London, England), 2013. PMID 23683600
- Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
Randomized trialKendler DL, Marin F, Zerbini CAF, et al. Lancet (London, England), 2018. PMID 29129436
- Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
ReviewDavis S, Simpson E, Hamilton J, et al. Health technology assessment (Winchester, England), 2020. PMID 32588816
- Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial
Randomized trialSim IW, Borromeo GL, Tsao C, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. PMID 32614699
- Teriparatide
StudyVall H, Patel P, Parmar M , 2024. PMID 32644674
- Teriparatide
Review, 2012. PMID 31644031
Search used: ("Teriparatide"[ti]). Run it on PubMed
Enlaces de investigación
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for Teriparatide on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.